Europe Carrier Testing Services Market Size and Forecast (2021 - 2031)

The Europe Carrier Testing Services Market is projected to grow significantly, reaching an estimated US$ 610.3 million by 2031, up from US$ 212.0 million in 2024. This growth reflects a robust compound annual growth rate (CAGR) of 16.7% from 2025 to 2031.

Executive Summary and Market Analysis

The carrier testing services market in Europe is categorized into several key regions, including Germany, the UK, France, Spain, Italy, and the Rest of Europe. The evolution of carrier testing services in this region is being propelled by supportive public health systems and various government initiatives. Countries such as the UK, Germany, and France are increasingly integrating carrier screening into their standard prenatal and preconception care protocols. The presence of a well-established network of over 900 genetic counselors across Europe enhances the transition from testing to effective patient care.

Historically, parts of Europe have engaged in population screening for inherited disorders, with Mediterranean countries implementing voluntary thalassemia carrier programs for decades. Recently, even non-endemic countries have begun to adopt similar screening practices. European laboratories are progressively adopting advanced technologies, including next-generation sequencing (NGS) and bioinformatics, to provide more comprehensive and accurate carrier panels.

The regulatory and reimbursement landscapes vary significantly across different countries, necessitating that companies navigate a complex web of policies. Growth opportunities for businesses can arise from public health-led screening initiatives or private services aimed at individuals seeking genetic risk assessments prior to pregnancy. As awareness of genetic testing increases and infrastructure improves, the region is set for a steady rise in carrier testing services.

Strategic Insights

# Market Segmentation Analysis

The Europe Carrier Testing Services Market can be segmented by type, medical conditions, and end users:

• By Type: The market is divided into Expanded Carrier Screening (ECS) and Targeted Disease Carrier Screening. The ECS segment is expected to dominate the market in 2024 due to its ability to screen for multiple conditions simultaneously.
• By Medical Conditions: The market is categorized into Pulmonary Conditions, Hematological Conditions, Neurological Conditions, and Other Medical Conditions. The Pulmonary Conditions segment is anticipated to lead the market in 2024.
• By End User: The market is segmented into Hospital-Based Laboratories, Diagnostic Laboratories, and Other End Users, with Hospital-Based Laboratories expected to hold the largest share in 2024.

Market Outlook

As the demand for comprehensive and transparent insights into genetic risks for families and healthcare providers grows, expanded carrier screening (ECS) is becoming increasingly relevant. ECS allows for the simultaneous screening of hundreds of genetic conditions, making it suitable for diverse populations. This broader approach minimizes the risk of missing hidden carriers, thereby facilitating safer reproductive planning through the availability of critical information.

For testing firms, ECS presents a unique opportunity to differentiate their services by offering high-coverage panels that are accessible and tailored to modern, diverse patient needs. The rising awareness of genetic conditions and a proactive approach to family planning are key drivers of the anticipated growth in ECS demand. Additionally, advancements in sequencing technology are reducing costs, enabling companies to offer competitive pricing for high-value testing.

ECS is fostering collaborations among fertility clinics, OB-GYN practitioners, telehealth providers, and digital health platforms, integrating screening into routine care. As ECS supports early decision-making and alleviates anxiety for prospective parents, it is increasingly recommended as part of standard preconception and prenatal care workflows. This shift towards broader and more accessible genetic testing allows companies to meet the growing consumer expectations in preventive and personalized healthcare, thereby strengthening their market position.

Country Insights

The Europe Carrier Testing Services Market is further segmented by country, including Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. The Rest of Europe accounted for the largest market share in 2024, with countries like Belgium, Russia, Luxembourg, Ukraine, Croatia, Cyprus, Romania, Slovakia, and Slovenia contributing significantly to the market.

In many European nations, genetic testing and counseling are integrated into national healthcare systems, although there are variations in regulatory frameworks and adoption rates. While genetic counselors are present in many countries, in some regions, the role is still primarily held by physicians. Carrier screening programs for disorders such as thalassemia, spinal muscular atrophy, and cystic fibrosis are often led by medical genetics departments or small public health initiatives. The adoption of NGS-based panels is on the rise, driven by cross-border collaborations and private sector investments.

The European market presents a diverse landscape for companies to penetrate through clinical genetics collaborations, partnerships with fertility clinics, and specialized laboratories. However, businesses must navigate country-specific regulations, infrastructure maturity, and reimbursement complexities.

Company Profiles

Key players in the Europe Carrier Testing Services Market include F. Hoffmann-La Roche Ltd, Quest Diagnostics Inc, Eurofins Scientific SE, Myriad Genetics Inc, Laboratory Corp of America Holdings, MedGenome Inc, Gene By Gene Ltd, Thermo Fisher Scientific Inc., Fulgent Genetics, Inc, and Illumina, Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.